Discuss, Share, and Engage
Infliximab and Cyclosporine and Risk of Colectomy in Hospitalized Patients with UC Complicated by CMV
A study published in Inflammatory Bowel Diseases evaluates:
Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus—A Multicenter Retrospective Study
The aim of this study was to compare the outcome of CMV-positive hospitalized patients with UC treated with antiviral therapy either alone or combined with salvage anti-inflammatory therapy (infliximab [IFX] or cyclosporine A [CsA]).
Interestingly, the authors found that IFX or cyclosporine therapy is not associated with additional risk for colectomy over antiviral therapy alone in hospitalized CMV-positive patients with UC
Inflammatory Bowel Diseases: September 2017 - Volume 23 - Issue 9 - p 1605–1613
ulcerative colitis, cytomegalovirus, infliximab, cyclosporine